Lactobacillus crispatus BC1 Biosurfactant Counteracts the Infectivity of Chlamydia trachomatis Elementary Bodies

Lactobacilli-derived biosurfactants (BS) have shown promising effects as antimicrobial molecules. Since Lactobacillus crispatus plays a crucial role in maintaining vaginal eubiosis, BS from this species could represent novel therapeutic agents to counteract sexually transmitted pathogens, such as Chlamydia trachomatis (CT). The aim of the present study was to assess the inhibitory effects of a BS produced by the vaginal strain L. crispatus BC1 on the infectivity of CT elementary bodies (EBs). For concentrations ranging between 1 and 0.5 mg/mL at 60-min contact time, L. crispatus BC1 BS displayed a highly significant anti-CT activity, with about 50% reduction of EB infectivity towards HeLa cells. To identify the components responsible for chlamydial inhibition, a panel of selected fatty acids, including those present in BS lipopeptidic structure, was tested against CT EBs. Pentadecanoic acid, myristic acid, β-hydroxy-myristic acid, and β-hydroxy-palmitic acid were able to significantly reduce EBs infectivity up to 5–0.5 µg/mL, concentrations that resulted to be non-toxic for HeLa cells. These data can contribute to the understanding of the biological role of lactobacilli in the vaginal niche, as well as to promote the application of their produced BS as an innovative and antibiotic-sparing anti-chlamydial strategy.

[1]  B. Luppi,et al.  Lactobacillus crispatus BC1 Biosurfactant Delivered by Hyalurosomes: An Advanced Strategy to Counteract Candida Biofilm , 2021, Antibiotics.

[2]  S. Randell,et al.  Human Fallopian Tube Epithelial Cell Culture Model To Study Host Responses to Chlamydia trachomatis Infection , 2020, Infection and Immunity.

[3]  B. Luppi,et al.  Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion , 2020, Microbial Cell Factories.

[4]  R. Gugasyan,et al.  Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota , 2020, Frontiers in Cellular and Infection Microbiology.

[5]  Andrew M. Bodratti,et al.  Biosurfactants, natural alternatives to synthetic surfactants: Physicochemical properties and applications. , 2019, Advances in colloid and interface science.

[6]  Vipan Kakkar,et al.  Crosstalk between vaginal microbiome and female health: A review. , 2019, Microbial pathogenesis.

[7]  C. Foschi,et al.  In-vitro effect of vaginal lactobacilli against group B Streptococcus. , 2019, Microbial pathogenesis.

[8]  C. Consolandi,et al.  Diversity of vaginal microbiome and metabolome during genital infections , 2019, Scientific Reports.

[9]  Y. S. Kurniawan,et al.  Antibacterial and Antifungal Activity of Three Monosaccharide Monomyristate Derivatives , 2019, Molecules.

[10]  P. Gajer,et al.  The Cervicovaginal Microbiota-Host Interaction Modulates Chlamydia trachomatis Infection , 2019, mBio.

[11]  B. Luppi,et al.  Liposomes containing biosurfactants isolated from Lactobacillus gasseri exert antibiofilm activity against methicillin resistant Staphylococcus aureus strains , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  N. Calonghi,et al.  Lactobacillus crispatus BC5 Interferes With Chlamydia trachomatis Infectivity Through Integrin Modulation in Cervical Cells , 2018, Front. Microbiol..

[13]  C. Foschi,et al.  Vaginal Lactobacilli Reduce Neisseria gonorrhoeae Viability through Multiple Strategies: An in Vitro Study , 2017, Front. Cell. Infect. Microbiol..

[14]  C. Rock,et al.  Exogenous fatty acid metabolism in bacteria. , 2017, Biochimie.

[15]  R. J. Alves,et al.  Biological and physicochemical properties of biosurfactants produced by Lactobacillus jensenii P6A and Lactobacillus gasseri P65 , 2017, Microbial Cell Factories.

[16]  L. Margolis,et al.  Vaginal Lactobacillus Inhibits HIV-1 Replication in Human Tissues Ex Vivo , 2017, Front. Microbiol..

[17]  N. Cho,et al.  Natural Products for the Treatment of Chlamydiaceae Infections , 2016, Microorganisms.

[18]  I. Banat,et al.  Biosurfactant/s from Lactobacilli species: Properties, challenges and potential biomedical applications , 2016, Journal of basic microbiology.

[19]  L. Laghi,et al.  Lactobacillus crispatus inhibits the infectivity of Chlamydia trachomatis elementary bodies, in vitro study , 2016, Scientific Reports.

[20]  Deepansh Sharma,et al.  Functional characterization of biomedical potential of biosurfactant produced by Lactobacillus helveticus , 2016, Biotechnology reports.

[21]  G. Zhong,et al.  An optimized, fast-to-perform mouse lung infection model with the human pathogen Chlamydia trachomatis for in vivo screening of antibiotics, vaccine candidates and modified host-pathogen interactions. , 2016, Pathogens and disease.

[22]  S. Abe,et al.  Inhibitory effects of several saturated fatty acids and their related fatty alcohols on the growth of Candida albicans. , 2015, Drug discoveries & therapeutics.

[23]  E. Scotti,et al.  Chlamydia pneumoniae acute liver infection affects hepatic cholesterol and triglyceride metabolism in mice. , 2015, Atherosclerosis.

[24]  L. Laghi,et al.  Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity , 2015, PloS one.

[25]  R. Cone,et al.  Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis , 2015, Front. Physiol..

[26]  H. Fan,et al.  Lactobacilli Inactivate Chlamydia trachomatis through Lactic Acid but Not H2O2 , 2014, PloS one.

[27]  G. Schiavoni,et al.  Effects of vaginal lactobacilli in Chlamydia trachomatis infection. , 2014, International journal of medical microbiology : IJMM.

[28]  P. Teixeira,et al.  The role of lactobacilli and probiotics in maintaining vaginal health , 2014, Archives of Gynecology and Obstetrics.

[29]  Eduardo J. Gudiña,et al.  Potential therapeutic applications of biosurfactants. , 2013, Trends in pharmacological sciences.

[30]  C. Hoebe,et al.  Detection of Anorectal and Cervicovaginal Chlamydia Trachomatis Infections following Azithromycin Treatment: Prospective Cohort Study with Multiple Time-Sequential Measures of rRNA, DNA, Quantitative Load and Symptoms , 2013, PloS one.

[31]  D. De Angelis,et al.  Risk of Pelvic Inflammatory Disease Following Chlamydia trachomatis Infection: Analysis of Prospective Studies With a Multistate Model , 2013, American journal of epidemiology.

[32]  K. Senior.  Chlamydia: a much underestimated STI. , 2012, The Lancet. Infectious diseases.

[33]  J. Ebersole,et al.  Short- and medium-chain fatty acids exhibit antimicrobial activity for oral microorganisms. , 2011, Archives of oral biology.

[34]  N. Low,et al.  Risk of sequelae after Chlamydia trachomatis genital infection in women. , 2010, The Journal of infectious diseases.

[35]  Matteo Ricchi,et al.  Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes , 2009, Journal of gastroenterology and hepatology.

[36]  L. Wojtczak,et al.  Fatty acids as modulators of the cellular production of reactive oxygen species. , 2008, Free radical biology & medicine.

[37]  K. Peeyananjarassri,et al.  Selection and identification of anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. , 2006, FEMS immunology and medical microbiology.

[38]  R. Rank,et al.  Characterization of Chlamydial Genital Infection Resulting from Sexual Transmission from Male to Female Guinea Pigs and Determination of Infectious Dose , 2003, Infection and Immunity.

[39]  Marc Prentki,et al.  Saturated Fatty Acid-induced Apoptosis in MDA-MB-231 Breast Cancer Cells , 2003, Journal of Biological Chemistry.

[40]  H. Thormar,et al.  In Vitro Killing of Candida albicans by Fatty Acids and Monoglycerides , 2001, Antimicrobial Agents and Chemotherapy.

[41]  S. Shott,et al.  Defense factors of vaginal lactobacilli. , 2001, American journal of obstetrics and gynecology.

[42]  H. Thormar,et al.  In Vitro Susceptibilities of Neisseria gonorrhoeae to Fatty Acids and Monoglycerides , 1999, Antimicrobial Agents and Chemotherapy.

[43]  H. Thormar,et al.  In Vitro Inactivation of Chlamydia trachomatis by Fatty Acids and Monoglycerides , 1998, Antimicrobial Agents and Chemotherapy.

[44]  S. Ledoux,et al.  Palmitate induced mitochondrial deoxyribonucleic acid damage and apoptosis in l6 rat skeletal muscle cells. , 2007, Endocrinology.